{"id":"W4293786422","doi":"10.1182/bloodadvances.2022007779","title":"Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results","year":2022,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"Novartis Pharmaceuticals Corporation","keywords":"Pembrolizumab; Medicine; Internal medicine; Oncology; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001475397,0.0008879259,0.001025277,0.0003022821,0.0002263252,0.0009395432,0.0006638656,0.0005552846,0.001993718],"category_scores_gemma":[0.0008086439,0.0003078555,0.0008970337,0.0002286684,0.0004473973,0.0005254922,0.0003437141,0.002274827,0.0005380551],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008085701,"about_ca_system_score_gemma":0.0008798284,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005415352,"about_ca_topic_score_gemma":0.001062001,"domain_scores_codex":[0.9995969,0.0002062872,0.00002314129,0.00006088987,0.00005571111,0.00005700301],"domain_scores_gemma":[0.9995944,0.00006054386,0.0001048741,0.00004205301,0.00004151609,0.0001566516],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5804653,0.06177613,0.01915579,0.001042373,0.002306562,0.0004624803,0.0002609028,0.005005393,0.1282921,0.0004860657,0.008863429,0.1918836],"study_design_scores_gemma":[0.3736256,0.5192383,0.05961144,0.0000917502,0.001812903,0.001118587,0.00008736899,0.005654324,0.02328541,0.0003773684,0.01501439,0.00008260019],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9926624,0.002257025,0.0004803979,0.000377378,0.00005662376,0.0007403406,0.0009603025,0.0001200018,0.002345381],"genre_scores_gemma":[0.9910837,0.001310862,0.001385184,0.0006439735,0.0001113315,0.0009135834,0.002620492,0.00004080834,0.001890147],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001993718,"threshold_uncertainty_score":0.007802725,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01465723839911933,"score_gpt":0.3169344250916463,"score_spread":0.302277186692527,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}